News
Trial results, approvals, pricing changes, safety findings and market moves across peptides and GLP-1 medications — each traced to a primary source, each dated. For enforcement actions specifically, see the regulatory tracker.
- Trial results
- Approvals
- Pricing changes
- Safety findings
-
Fat inside the thigh muscle fell on semaglutide, in a 55-person MRI substudy
Read more: Fat inside the thigh muscle fell on semaglutide, in a 55-person MRI substudySemaglutide’s highest-dose weight-loss trial put a small group of its participants inside an MRI scanner, and the results speak to the question that trails every GLP-1 drug: what happens to muscle. Among 55 people drawn from the 1,407-person STEP UP trial, fat volume fell sharply over 72 weeks, thigh muscle volume fell by an amount…
-
A cardiology team catalogues the injectable-peptide market, compound by compound
Read more: A cardiology team catalogues the injectable-peptide market, compound by compoundThree physicians at the University of Missouri-Kansas City and Saint Luke’s Mid America Heart Institute have published a review that does something the injectable-peptide market rarely gets: a compound-by-compound account of what is claimed, what mechanism is proposed, and what could go wrong. It covers BPC-157, TB-500, CJC-1295 and ipamorelin, MK-677, melanotan-II, GHK-Cu, retatrutide and…
-
11.3% of body weight lost, 1.46 kg of it muscle, in 388 scanned patients
Read more: 11.3% of body weight lost, 1.46 kg of it muscle, in 388 scanned patientsThree endocrinology clinics in Madrid scanned 388 adults with obesity four times over six months on GLP-1 drugs and report that skeletal muscle mass fell by 1.46 kg while mean body weight fell 11.3%. Visceral fat area dropped by 40.6 square centimetres. On those numbers the muscle loss is modest next to the fat loss,…
-
37 brain-imaging studies on GLP-1 drugs, and the one consistent finding
Read more: 37 brain-imaging studies on GLP-1 drugs, and the one consistent findingResearchers at the National Institute on Alcohol Abuse and Alcoholism have gone through every human brain-imaging study of GLP-1 drugs they could find – 37 of them – and report one reasonably consistent result: a single dose blunts the brain’s response to reward. Almost everything else is less settled than the popular account suggests. The…
-
CagriSema beat semaglutide by 6.6 points across eight trials
Read more: CagriSema beat semaglutide by 6.6 points across eight trialsA combination of semaglutide and a second injected hormone analogue produced about 6.6 percentage points more weight loss than semaglutide on its own, according to a meta-analysis of eight randomised trials in 6,898 people published on 15 September. The combination, CagriSema, is not something a reader in the United States can fill a prescription for:…
-
Route of administration outranked weight loss in an 800-person preference survey
Read more: Route of administration outranked weight loss in an 800-person preference surveyAsked to choose between hypothetical weight-loss drugs, 800 American adults ranked how a drug is taken above how much weight it takes off. In a discrete-choice survey published on 17 September, route of administration was the single most important attribute driving choice, ahead of average weight loss, cardiovascular risk reduction and the share of people…
-
Spine-fusion complications didn’t rise on GLP-1 drugs across 28,525 patients
Read more: Spine-fusion complications didn’t rise on GLP-1 drugs across 28,525 patientsIf you take a GLP-1 drug and have spinal fusion surgery scheduled, the largest synthesis of the evidence so far found no sign that the drug makes the operation riskier. A systematic review and meta-analysis published on 17 September pooled seven studies covering 28,525 adults who underwent lumbar fusion, and found no statistically significant difference…
-
Only 3 in 10 adults were still taking a GLP-1 drug consistently after a year
Read more: Only 3 in 10 adults were still taking a GLP-1 drug consistently after a yearFewer than a third of commercially insured US adults who started a GLP-1 drug for obesity were still taking it consistently a year later, an analysis of 201,229 claims records has found. About 64% fell into one of three discontinuation patterns: stopping almost immediately, stopping within a few months, or tailing off later in the…
-
1 in 6 teenagers on a GLP-1 drug had a nutritional deficiency recorded within a year
Read more: 1 in 6 teenagers on a GLP-1 drug had a nutritional deficiency recorded within a yearJust under 17% of 10- to 17-year-olds who started a GLP-1 drug were diagnosed with a nutritional deficiency or a related complication within the following year, an analysis of US insurance claims has found. Most of those diagnoses were vitamin D deficiency. Fewer than a quarter of the teenagers saw anyone for nutrition counselling within…
-
Gut bacteria measured beforehand helped predict who kept weight off after a 5-day fast
Read more: Gut bacteria measured beforehand helped predict who kept weight off after a 5-day fastA five-day fast produced a fall in body mass index that was still partly present twelve weeks later, and the mix of bacteria in a person’s gut beforehand helped predict how much of it they kept, according to a randomised trial published on 16 September in Genome Medicine. The study involved 38 healthy adults under…